Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Accenture
Boehringer Ingelheim
Dow
McKesson
Citi
Cipla
Merck

Generated: December 10, 2018

DrugPatentWatch Database Preview

RENFLEXIS Drug Profile

« Back to Dashboard

Summary for Tradename: RENFLEXIS
Patents:0
Applicants:1
BLAs:1
Suppliers: see list1

US Patents for RENFLEXIS

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Samsung Bioepsis Co Ltd RENFLEXIS infliximab-abda INJECTABLE;INJECTION 761054 001 2017-04-21 ➤ Sign Up ➤ Sign Up RX
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKinsey
Cipla
Daiichi Sankyo
Accenture
Fuji
Cantor Fitzgerald
Federal Trade Commission
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.